Danaher expects Q4 non-GAAP core revenue growth high-single digits, above prior guidance

DANAHER CORP /DE/

2022-FY EPS reported $9.66 revenue$31,471,000,000

Q4 estimated revenues up low-single-digit% YoY; non-GAAP core revenue growth high-single-digit% vs prior flat to low-single-digit decline guidance.
Base business core revenue growth high-single-digit%, in line with previous guidance.
Cepheid respiratory testing revenue exceeded $1B in Q4.
Full Q4 and FY 2022 earnings call scheduled for Jan 24, 2023 at 8:00 a.m. ET.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

DANAHER CORP /DE/ reported fourth quarter 2022 results: revenue increase in the low-single digit percent range year-over-year. Guidance reaffirmed.

Period: fourth quarter 2022
Revenue: increase in the low-single digit percent range year-over-year
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

For the fourth quarter 2022, estimated revenues are anticipated to increase in the low-single digit percent range year-over-year.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DANAHER CORP /DE/ filing history →

Source: SEC EDGAR

accession 0000313616-23-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.